The endocannabinoid 2-Arachidonoylglycerol (2-AG) (17), the CB1 and CB2 receptors (30), and the enzyme (31) all have antidepressant pharmacological modulation and are potential new therapeutic targets for the treatment of MDD. Here, CNR1 is linked to major depressive disorder.